What does this research mean for the field?

Neoadjuvant chemoimmunotherapy is associated with a lower incidence of early recurrence, particularly distant metastasis, and better overall survival compared to neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To compare early recurrence patterns and long-term survival outcomes between neoadjuvant chemoimmunotherapy (NCIT) and neoadjuvant chemoradiotherapy (NCRT) in locally advanced esophageal squamous cell carcinoma.

September 10, 2026European Journal of Cardio-Thoracic SurgeryOpen Access

Early recurrence patterns after neoadjuvant chemoradiotherapy and chemoimmunotherapy in esophageal squamous cell carcinoma: A multicenter study

View Full Paper

Ask AI

Bookmark

Authors

CSCien Sun CCChunji Chen HSHua Sun

Discussion

Member takes

Overview

Retrospective cohort study reveals lower early recurrence and improved survival with neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma, indicating superior systemic control.

Key Points

To compare early recurrence patterns and long-term survival outcomes between neoadjuvant chemoimmunotherapy (NCIT) and neoadjuvant chemoradiotherapy (NCRT) in locally advanced esophageal squamous cell carcinoma.
Retrospective multicenter cohort study analyzing 1,428 patients with stage IIB–IVA esophageal squamous cell carcinoma who received NCIT or NCRT prior to radical surgery.
Propensity score matching (1:1 ratio, 0.1 caliper) established balanced cohorts of 532 patients per group.
Multivariable Cox proportional hazards regression assessed risk factors for early recurrence, distant metastasis, overall survival (OS), and post-recurrence survival (PRS).
NCIT demonstrated superior 3-year OS (72.2% vs 60.9%; HR, 0.69; 95% CI, 0.56–0.85; P < .001) and 3-year RFS (67.8% vs 59.3%; HR, 0.70; 95% CI, 0.57–0.86; P < .001) compared with NCRT.
Patients treated with NCIT had significantly lower rates of early overall recurrence (24.6% vs 36.8%; P < .001) and early distant metastasis (13.7% vs 23.5%; P < .001).
Early recurrence post-recurrence survival did not differ between treatments (HR, 0.81; 95% CI, 0.63–1.04; P = .086), while NCRT, elevated ypN stage, and absence of major pathological response independently predicted early relapse.

Cite This Study

Sun et al. (2026) studied this question.

synapsesocial.com/papers/6aa27c2058559d80afc75c19 https://doi.org/10.1093/ejcts/ezag219

View Full Paper

Ask AI

Bookmark

September 10, 2026European Journal of Cardio-Thoracic SurgeryOpen Access

Early recurrence patterns after neoadjuvant chemoradiotherapy and chemoimmunotherapy in esophageal squamous cell carcinoma: A multicenter study

View Full Paper

Ask AI

Bookmark

Authors

CSCien Sun CCChunji Chen HSHua Sun

Discussion

Member takes

Overview

Retrospective cohort study reveals lower early recurrence and improved survival with neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma, indicating superior systemic control.

Key Points

To compare early recurrence patterns and long-term survival outcomes between neoadjuvant chemoimmunotherapy (NCIT) and neoadjuvant chemoradiotherapy (NCRT) in locally advanced esophageal squamous cell carcinoma.
Retrospective multicenter cohort study analyzing 1,428 patients with stage IIB–IVA esophageal squamous cell carcinoma who received NCIT or NCRT prior to radical surgery.
Propensity score matching (1:1 ratio, 0.1 caliper) established balanced cohorts of 532 patients per group.
Multivariable Cox proportional hazards regression assessed risk factors for early recurrence, distant metastasis, overall survival (OS), and post-recurrence survival (PRS).
NCIT demonstrated superior 3-year OS (72.2% vs 60.9%; HR, 0.69; 95% CI, 0.56–0.85; P < .001) and 3-year RFS (67.8% vs 59.3%; HR, 0.70; 95% CI, 0.57–0.86; P < .001) compared with NCRT.
Patients treated with NCIT had significantly lower rates of early overall recurrence (24.6% vs 36.8%; P < .001) and early distant metastasis (13.7% vs 23.5%; P < .001).
Early recurrence post-recurrence survival did not differ between treatments (HR, 0.81; 95% CI, 0.63–1.04; P = .086), while NCRT, elevated ypN stage, and absence of major pathological response independently predicted early relapse.

Cite This Study

Sun et al. (2026) studied this question.

synapsesocial.com/papers/6aa27c2058559d80afc75c19 https://doi.org/10.1093/ejcts/ezag219

View Full Paper

Ask AI

Bookmark